BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17569256)

  • 1. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
    Bai Q; Chen F; Qi J; Chen JH; Wang YX
    Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
    Craft N; Shostak Y; Carey M; Sawyers CL
    Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu expression in prostate cancer: a dynamic process?
    Carles J; Lloreta J; Salido M; Font A; Suarez M; Baena V; Nogue M; Domenech M; Fabregat X
    Clin Cancer Res; 2004 Jul; 10(14):4742-5. PubMed ID: 15269147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
    Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
    Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
    Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
    Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.
    Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK
    Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
    Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
    Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Androgen-independent prostate carcinoma and androgen-receptor: recent progress in molecular genetics].
    Sultan C; Terouanne B; Tahiri B; Lumbroso S; Avances C; Orio F
    Bull Cancer; 1999; 86(7-8):618-21. PubMed ID: 10477378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
    Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
    Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
    Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
    Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
    Ricciardelli C; Jackson MW; Choong CS; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2008 Jun; 68(8):830-8. PubMed ID: 18324648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal receptor-2 expression in prostate cancer.
    Calvo BF; Levine AM; Marcos M; Collins QF; Iacocca MV; Caskey LS; Gregory CW; Lin Y; Whang YE; Earp HS; Mohler JL
    Clin Cancer Res; 2003 Mar; 9(3):1087-97. PubMed ID: 12631612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
    Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
    Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
    Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
    J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer.
    Nishio Y; Yamada Y; Kokubo H; Nakamura K; Aoki S; Taki T; Honda N; Nakagawa A; Saga S; Hara K
    Urology; 2006 Jul; 68(1):110-5. PubMed ID: 16806433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
    Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
    J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.